Φορτώνει......
Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Anti-EGFR therapy and antiangiogenic therapies are used alone or in combination with chemotherapies to improve survival in metastatic colorectal cancer. However, it is unknown whether pretreatment with antiangiogenic therapy could impact on the efficacy of anti-EGFR therapy. We selected one hundred...
Αποθηκεύτηκε σε:
Τόπος έκδοσης: | Oncotarget |
---|---|
Κύριοι συγγραφείς: | , , , , , , , , , , |
Μορφή: | Artigo |
Γλώσσα: | Inglês |
Έκδοση: |
Impact Journals LLC
2016
|
Θέματα: | |
Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4891042/ https://ncbi.nlm.nih.gov/pubmed/26824184 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7008 |
Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|